Optimizing Reperfusion to Improve Outcomes and Neurologic Function

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 740 participants.

Also called NCT06990867

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 740 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06990867
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Bulgaria, Canada, China, France, Germany, Greece, Hungary, Italy, Japan, Latvia, Lithuania, Malaysia, Portugal, Serbia, South Korea, Spain, Thailand, United Kingdom, Vietnam (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06990867. Randomized; quadruple masking; primary purpose treatment. Start 2025-05-15 (actual); primary completion 2029-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Acronym
ORION
Condition
Acute Ischemic Stroke
Intervention (Drug)
JX10
Intervention (Drug)
Placebo
Lead sponsor
Corxel Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct06990867
Content hash
5370e6ec1da999c435c7b01b32e9df6f4d02dc3a5419090a7651305259b5bde9